Precigen (PGEN) Income from Non-Controlling Interests (2012 - 2019)
Precigen (PGEN) reported Income from Non-Controlling Interests of -$165000.0 for Q2 2019, up 88.6% year-over-year from -$87488.1 in Q2 2018, and up 88.44% quarter-over-quarter from -$1.4 million in Q1 2019.
Precigen (PGEN) Income from Non-Controlling Interests (2012 - 2019) Analysis & Trends
Precigen (PGEN) has 8 years of Income from Non-Controlling Interests data on file, last reported at -$165000.0 in Q2 2019.
- Income from Non-Controlling Interests for Q2 2019 came in at -$165000.0, up 88.6% year-over-year; the trailing twelve-month figure through Mar 2020 was -$165000.0 (up 97.03% YoY), and the FY2019 annual result was -$1.6 million, up 70.35% from the prior year.
- Income from Non-Controlling Interests advanced to -$165000.0 in Q2 2019 per PGEN's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$165000.0 in Q2 2019 and troughed at -$6.7 million in Q4 2017.
- A 5-year average of -$1.3 million and a median of -$1.0 million in 2016 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2017 and 2019: Income from Non-Controlling Interests plunged 761.81% in 2017, then jumped 88.6% in 2019.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$561000.0 in 2015, then plunged by 38.15% to -$775000.0 in 2016, then tumbled by 761.81% to -$6.7 million in 2017, then surged by 81.18% to -$1.3 million in 2018, then soared by 86.87% to -$165000.0 in 2019.
- Business Quant data shows PGEN's Income from Non-Controlling Interests at -$165000.0 in Q2 2019, -$1.4 million in Q1 2019, and -$1.3 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -165,000.00 |
| Mar 31, 2019 | -1.43 Mn |
| Dec 31, 2018 | -1.26 Mn |
| Sep 30, 2018 | -1.42 Mn |
| Jun 30, 2018 | -1.45 Mn |
| Mar 31, 2018 | -1.24 Mn |
| Dec 31, 2017 | -6.68 Mn |
| Sep 30, 2017 | -1.15 Mn |
| Jun 30, 2017 | -998,000.00 |
| Mar 31, 2017 | -978,000.00 |
| Dec 31, 2016 | -775,000.00 |
| Sep 30, 2016 | -1.03 Mn |
| Jun 30, 2016 | -967,000.00 |
| Mar 31, 2016 | -891,000.00 |
| Dec 31, 2015 | -561,000.00 |
| Sep 30, 2015 | -816,000.00 |
| Jun 30, 2015 | -831,000.00 |
| Mar 31, 2015 | -1.29 Mn |
| Dec 31, 2014 | -899,000.00 |
| Sep 30, 2014 | -1.14 Mn |